| ŠPINAR, Jindřich, Jiří VÍTOVEC, Miroslav SOUČEK, Lenka ŠPINAROVÁ, Růžena LÁBROVÁ, Martina ŠIŠÁKOVÁ, Jiří JARKOVSKÝ, Jiří ŠPÁC and Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. Experimental and Clinical Cardiology. Ontario: Pulsus Group, 2014, vol. 20, No 1, p. 662-673. ISSN 1205-6626. |
Other formats:
BibTeX
LaTeX
RIS
@article{1194852,
author = {Špinar, Jindřich and Vítovec, Jiří and Souček, Miroslav and Špinarová, Lenka and Lábrová, Růžena and Šišáková, Martina and Jarkovský, Jiří and Špác, Jiří and Ondrejková, Alena},
article_location = {Ontario},
article_number = {1},
keywords = {Atrial fibrillation; Bleeding; Dabigatran; Risk; Warfarin},
language = {eng},
issn = {1205-6626},
journal = {Experimental and Clinical Cardiology},
title = {The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation},
volume = {20},
year = {2014}
}
TY - JOUR
ID - 1194852
AU - Špinar, Jindřich - Vítovec, Jiří - Souček, Miroslav - Špinarová, Lenka - Lábrová, Růžena - Šišáková, Martina - Jarkovský, Jiří - Špác, Jiří - Ondrejková, Alena
PY - 2014
TI - The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation
JF - Experimental and Clinical Cardiology
VL - 20
IS - 1
SP - 662-673
EP - 662-673
PB - Pulsus Group
SN - 12056626
KW - Atrial fibrillation
KW - Bleeding
KW - Dabigatran
KW - Risk
KW - Warfarin
N2 - Aim: The FIRST registry aimed to compare patients with atrial fibrillation treated with dabigatran or warfarin. Methods: The study was performed in 10 centres in the Czech Republic. Results: Upon enrolment, 33.2% and 35.6% of patients respectively showed sinus rhythm. The last dose of warfarin before changing to dabigatran was higher than the maintenance dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients did not differ in the CHA2DS2-VASc score. The principal difference was in the HAS BLED score: 55.3% of patients treated with dabigatran demonstrated a score of three or more while only 33.5% of those treated with warfarin did (p < 0.001). In 14.7% of patients treated with dabigatran, serious bleeding was observed during the previous treatment with warfarin. In patients treated with warfarin serious bleeding occurred in 2.0%. The most frequent reason (56.6%) for changing over to dabigatran was the impossibility to maintain INR within the therapeutic range. Conclusion: Patients are transferred from warfarin to dabigatran in particular due to the impossibility to maintain INR within the therapeutic range, and these are more frequently patients with a higher bleeding risk.
ER -
ŠPINAR, Jindřich, Jiří VÍTOVEC, Miroslav SOUČEK, Lenka ŠPINAROVÁ, Růžena LÁBROVÁ, Martina ŠIŠÁKOVÁ, Jiří JARKOVSKÝ, Jiří ŠPÁC and Alena ONDREJKOVÁ. The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation. \textit{Experimental and Clinical Cardiology}. Ontario: Pulsus Group, 2014, vol.~20, No~1, p.~662-673. ISSN~1205-6626.
|
